R N Brogden, D H Peters
Index: Drugs 48(4) , 599-616, (1994)
Full Text: HTML
Dirithromycin is a new macrolide with a spectrum and degree of in vitro antimicrobial activity similar to that of erythromycin. Compared with erythromycin, dirithromycin has a long elimination half-life enabling once-daily administration, and it also achieves a greater cellular:extracellular concentration ratio and higher concentration in some tissues. Multicentre double-blind clinical trials have shown dirithromycin to be similar in efficacy to erythromycin in the treatment of uncomplicated bacterial infections of the respiratory tract and of skin and soft tissues. Since dirithromycin is at least as well tolerated as erythromycin, with its convenient administration schedule and pharmacokinetic profile it is a useful alternative to erythromycin in the treatment of appropriate community-acquired infections. Definition of the place of dirithromycin relative to that of the other newer macrolides awaits the results of further suitably designed therapeutic trials.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Dirithromycin
CAS:62013-04-1 |
C42H78N2O14 |
The new macrolide antibiotics: azithromycin, clarithromycin,...
1992-01-01 [Ann. Pharmacother. 26(1) , 46-55, (1992)] |
Pharmacokinetics of dirithromycin.
1993-03-01 [J. Antimicrob. Chemother. 31 Suppl C , 65-75, (1993)] |
Modulation of human polymorphonuclear neutrophil function by...
1993-03-01 [J. Antimicrob. Chemother. 31 Suppl C , 51-64, (1993)] |
Macrolide - induced clinically relevant drug interactions wi...
2000-10-01 [.PubMed ID] |
Drug interactions of macrolides: emphasis on dirithromycin.
1997-03-01 [Ann. Pharmacother. 31(3) , 349-56, (1997)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved